RBRC01678

Information1

Image
BRC No.RBRC01678
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameFVB.129P2-Nf2<tm1Gth>/GthRbrc
Former Common nameNF2KO3
H-2 Haplotype
ES Cell line
Background strainFVB/NJcl
Appearance
Strain development
Strain descriptionアスベストで引き起こされるMalignant Mesotheliomasの半数にこの遺伝子のmutationが見られる。Nf2 KO +/-マウスにアスベストを暴露すると高率でLOHが起こり、中皮腫を引き起こす。
Colony maintenance
ReferencesGenes Dev., 14, 1617-1630 (2000). 10887156

Health Report

Examination Date / Room / Rack2009/02/23Room:3-DRack:I
2008/12/15Room:3-DRack:I
2008/10/20Room:3-DRack:I
2008/08/25Room:3-DRack:I
2008/06/23Room:3-DRack:I
2008/04/22Room:3-DRack:I
2008/04/21Room:3-DRack:I
2008/02/18Room:3-DRack:I

Gene

Gene info
Gene symbolGene nameChr.Allele symbolAllele namePromoter
Nf2neurofibromatosis 211Nf2<tm1Gth>targeted mutation 1, Gilles Thomas

Gene symbolGene nameChr.Allele symbolAllele namePromoter
IRESinternal ribosomal entry site (EMCV)11

Gene symbolGene nameChr.Allele symbolAllele namePromoter
hyghygromycin phasphotransferase (E. coli)11hyg

Gene symbolGene nameChr.Allele symbolAllele namePromoter
lacZbeta-galactosidase (E. coli)11

Information2

供与核酸Encephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), E. coli lacZ, mouse Pgk promoter, E. coli Hyg, rabbit bata globin poly A
Research applicationNeurobiology Research
提供条件条件を付加する。利用者は事前に寄託者の提供承諾書を得る。
研究成果の公表にあたって寄託者の指定する文献を引用する。Genes & Development., 14, 1617-1630 (2000).
研究成果の公表にあたって謝辞の表明を必要とする。
RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
DepositorMarco Giovannini(INSERM)
Strain Status凍結胚のアイコン凍結胚
Strain Availability凍結胚より作出したマウスを2~4ヶ月以内に提供可能
凍結胚を1ヶ月以内に提供可能
Additional Info.Genotyping protocol -PCR-

BRC mice in Publications

No Data